Fecal Microbiota Transplantation
VIDEO: Rebyota effective in prevention of recurrent C. diff, even in higher risk patients
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
‘Some may die’: AGA urges continued access to conventional FMT for C. difficile patients
OpenBiome will continue distribution of investigational fecal microbiota transplantation through 2024, as suspension may put certain patients with recurrent, refractory or fulminant Clostridioides difficile at risk, according to the AGA.
Other Therapies
FMT safe, ‘could prevent’ recurrence of hepatic encephalopathy in patients with cirrhosis
Recurrence of hepatic encephalopathy was lower among patients with cirrhosis and hepatic encephalopathy who received oral capsule or enema fecal microbiota transplant vs. placebo, according to research from EASL Congress.
VIDEO: Real-world data confirm Rebyota’s ‘consistent’ efficacy in recurrent C. difficile
WASHINGTON — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses real-world results for Rebyota as a treatment of recurrent Clostridioides difficile infection, which were presented at Digestive Disease Week.
Q&A: ‘Future is bright’ for use of microbiota therapeutics in patients with IBD
In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.
Budesonide does not affect engraftment, clinical response after FMT in ulcerative colitis
Pretreatment with budesonide did not significantly influence engraftment among patients with ulcerative colitis who underwent fecal microbiota transplantation, with researchers reporting that clinical response appeared to be donor-dependent.
AGA guideline endorses FMT for recurrent C. difficile; ‘not yet advised’ for IBS, IBD
Although effective in select patients, the AGA advised against fecal microbiota-based therapies to prevent recurrent Clostridioides difficile infection in severely immunocompromised adults or to treat other gastrointestinal conditions.
Gut Check-in: Healio Gastroenterology recaps trends that will shape GI practice in 2024
From a shift in nomenclature for steatotic liver disease to how a boom in live biotherapeutics will revamp treatment for Clostridioides difficile infection, Healio was at the forefront of gastroenterology and hepatology coverage in 2023.